Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 nipocalimab study in adults with generalized myasthenia gravis
jRCT2021210027Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of nipocalimab in myasthenia gravis (MG) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Average change from baseline in MG-ADL score over Weeks 22, 23, and 24, Percent change in anti-AChR autoantibody titer and 1 more. Started Dec 2021; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2021210027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210027.